5 Reasons This Pharmacist-Led Team Left Big Pharma to Build Adoria

A team with decades inside the pharmaceutical industry walked away to build something the system was never designed to offer. Here's what they wanted people to actually understand — and why nobody had brought this specific approach to market before them.

Reason 1

We spent years watching medication manage symptoms while the actual damage ran unaddressed underneath it.

"Most of us spent the early parts of our careers inside the pharmaceutical side of chronic kidney disease management. ACE inhibitors, ARBs, the entire monitoring and adjustment protocol that defines standard care. These medications work exactly as they were designed to. They manage pressure. That is a real and necessary function. But pressure management was never the same thing as addressing the three cellular mechanisms actually driving the decline — the inflammatory cascade, the oxidative stress, the fibrosis. We watched patient after patient get told their numbers were 'stable' or 'manageable' for ten, fifteen years, while none of those three mechanisms were ever directly addressed by anything we were prescribing them."

Reason 2

The clinical research already existed. Nobody in our industry had a reason to act on it.

"There's a randomized controlled trial — 98 CKD patients, eGFR improving from 31.8 to 45.6 over three months, using Cordyceps militaris fruiting body extract at a specific clinical dose. A meta-analysis behind it covering over 1,300 patients across multiple study designs. This wasn't obscure. It was published, peer reviewed, sitting in the same medical literature we referenced every day. Nobody acted on it, because there was no mechanism inside the pharmaceutical industry to commercialize a mushroom. You cannot patent a naturally occurring fungus. Without a patent, there's no exclusivity, and without exclusivity, there's no return on the investment required to bring it to market through the channels we were used to working in."

Reason 3

We built Adoria specifically because nobody had brought this mechanism to market correctly, at the right dose, for this specific use.

"It would have been easier and cheaper to build something that gestured at the research without actually matching it — a smaller dose, a blend padded with cheaper ingredients to make the label look fuller than the formula actually was. We didn't do that. We built Adoria around fruiting body extract, hot-water extracted, at 3,000mg — the exact form and dose used in the actual published clinical trial. As far as we know, nobody else had brought a product to market built specifically and entirely around that research, at that dose, for kidney health specifically. That gap is the entire reason this company exists."

Reason 4

We published our Certificate of Analysis because that standard was never optional where we came from.

"In pharmaceutical manufacturing, every claim about a drug's contents is backed by disclosed, regulator-reviewed data. That's not a courtesy — it's a requirement. When we moved into building a supplement, we brought that same standard with us, even though nothing in the supplement industry required it of us. We publish our actual lab-verified cordycepin content, tested by an independent third party, because we spent our careers in an industry where unverified claims about a product's contents simply weren't acceptable, and we didn't see a reason to lower that bar just because the regulatory requirement no longer applied."

Reason 5

We built it to address three mechanisms simultaneously, because we'd seen firsthand that addressing only one was never going to be enough.

"Cordycepin directly suppresses the inflammatory cascade. Astaxanthin addresses the mitochondrial oxidative stress accumulating in kidney cells from the constant filtration workload. Alpha-lipoic acid provides additional cellular protection at that same level. We didn't formulate this around one ingredient solving everything, because we'd spent years watching single-mechanism pharmaceutical solutions fall short of the full picture. Standard treatment addresses pressure and stops there. We built Adoria specifically to address what the pharmaceutical side of this industry — the side we used to work inside of — was never designed to reach."